BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 38115146)

  • 21. BRAF(V600E) mutation analysis of liquid-based preparation-processed fine needle aspiration sample improves the diagnostic rate of papillary thyroid carcinoma.
    Chang H; Lee H; Yoon SO; Kim H; Kim A; Kim BH
    Hum Pathol; 2012 Jan; 43(1):89-95. PubMed ID: 21774961
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Metastatic thyroid carcinoma without identifiable primary tumor within the thyroid gland: a retrospective study of a rare phenomenon.
    Xu B; Scognamiglio T; Cohen PR; Prasad ML; Hasanovic A; Tuttle RM; Katabi N; Ghossein RA
    Hum Pathol; 2017 Jul; 65():133-139. PubMed ID: 28552827
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The role of BRAF(V600E) mutation as poor prognostic factor for the outcome of patients with intrathyroid papillary thyroid carcinoma.
    Pelizzo MR; Dobrinja C; Casal Ide E; Zane M; Lora O; Toniato A; Mian C; Barollo S; Izuzquiza M; Guerrini J; De Manzini N; Merante Boschin I; Rubello D
    Biomed Pharmacother; 2014 May; 68(4):413-7. PubMed ID: 24721322
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Detection of the BRAF(V600E) mutation in fine needle aspiration cytology of thyroid papillary microcarcinoma cells selected by manual macrodissection: an easy tool to improve the preoperative diagnosis.
    Marchetti I; Iervasi G; Mazzanti CM; Lessi F; Tomei S; Naccarato AG; Aretini P; Alberti B; Di Coscio G; Bevilacqua G
    Thyroid; 2012 Mar; 22(3):292-8. PubMed ID: 22181337
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Classic Architecture with Multicentricity and Local Recurrence, and Absence of TERT Promoter Mutations are Correlates of BRAF (V600E) Harboring Pediatric Papillary Thyroid Carcinomas.
    Onder S; Ozturk Sari S; Yegen G; Sormaz IC; Yilmaz I; Poyrazoglu S; Sanlı Y; Giles Senyurek Y; Kapran Y; Mete O
    Endocr Pathol; 2016 Jun; 27(2):153-61. PubMed ID: 26951110
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The correlation of sodium iodide symporter and BRAF(V600E) mutation in classical variant papillary thyroid carcinoma.
    Yazgan A; Yıldırım N; Gözalan A; Gümüştaş S; Kılıçarslan A; Balci S; Aydın C; Ersoy R; Cakir B; Güler G
    Ann Diagn Pathol; 2016 Jun; 22():58-62. PubMed ID: 27180062
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Associations between BRAF(V600E) and prognostic factors and poor outcomes in papillary thyroid carcinoma: a meta-analysis.
    Liu C; Chen T; Liu Z
    World J Surg Oncol; 2016 Sep; 14(1):241. PubMed ID: 27600854
    [TBL] [Abstract][Full Text] [Related]  

  • 28. BRAF mutation in papillary thyroid carcinoma in a Japanese population: its lack of correlation with high-risk clinicopathological features and disease-free survival of patients.
    Ito Y; Yoshida H; Maruo R; Morita S; Takano T; Hirokawa M; Yabuta T; Fukushima M; Inoue H; Tomoda C; Kihara M; Uruno T; Higashiyama T; Takamura Y; Miya A; Kobayashi K; Matsuzuka F; Miyauchi A
    Endocr J; 2009; 56(1):89-97. PubMed ID: 18840924
    [TBL] [Abstract][Full Text] [Related]  

  • 29. BRAF (V600E) mutation analysis on liquid-based cytology-processed aspiration biopsies predicts bilaterality and lymph node involvement in papillary thyroid microcarcinoma.
    Rossi ED; Martini M; Capodimonti S; Lombardi CP; Pontecorvi A; Vellone VG; Zannoni GF; Larocca LM; Fadda G
    Cancer Cytopathol; 2013 Jun; 121(6):291-7. PubMed ID: 23192956
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Correlation between BRAF
    Zhou B; Hei H; Li YQ; Zhang DY; Wang DQ; Qin JW
    Zhonghua Yi Xue Za Zhi; 2023 Apr; 103(14):1060-1063. PubMed ID: 37032157
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fine needle aspiration of follicular variant of papillary thyroid carcinoma presenting with pleural effusion: a case report.
    Siddaraju N; Viswanathan VK; Saka VK; Basu D; Shanmugham C
    Acta Cytol; 2007; 51(6):911-5. PubMed ID: 18077985
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Role of ultrasonographic/clinical profile, cytology, and BRAF V600E mutation evaluation in thyroid nodule screening for malignancy: a prospective study.
    Rossi M; Buratto M; Bruni S; Filieri C; Tagliati F; Trasforini G; Rossi R; Beccati MD; Degli Uberti EC; Zatelli MC
    J Clin Endocrinol Metab; 2012 Jul; 97(7):2354-61. PubMed ID: 22535974
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cytologic, clinicopathologic, and molecular features of papillary thyroid carcinoma with prominent hobnail features: 10 case reports and systematic literature review.
    Lee YS; Kim Y; Jeon S; Bae JS; Jung SL; Jung CK
    Int J Clin Exp Pathol; 2015; 8(7):7988-97. PubMed ID: 26339365
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Correlation between the BRAF V600E mutation status and the clinicopathologic features of papillary thyroid carcinoma.
    Shi CL; Sun Y; Ding C; Lv YC; Qin HD
    Genet Mol Res; 2015 Jul; 14(3):7377-85. PubMed ID: 26214416
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mutational analysis of metastatic lymph nodes from papillary thyroid carcinoma in adult and pediatric patients.
    Shifrin AL; Fischer M; Paul T; Erler B; Gheysens K; Baodhankar P; Song-Yang JW; Taylor S; Timmaraju VA; Topilow A; Mireskandari A; Kumar G
    Surgery; 2017 Jan; 161(1):176-187. PubMed ID: 27866718
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The BRAF(V600E) mutation in papillary thyroid microcarcinoma: does the mutation have an impact on clinical outcome?
    Walczyk A; Kowalska A; Kowalik A; Sygut J; Wypiórkiewicz E; Chodurska R; Pięciak L; Góźdź S
    Clin Endocrinol (Oxf); 2014 Jun; 80(6):899-904. PubMed ID: 24354346
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Value of immunohistochemistry in the detection of BRAF(V600E) mutations in fine-needle aspiration biopsies of papillary thyroid carcinoma.
    Zimmermann AK; Camenisch U; Rechsteiner MP; Bode-Lesniewska B; Rössle M
    Cancer Cytopathol; 2014 Jan; 122(1):48-58. PubMed ID: 24039206
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pancreatic metastasis arising from a BRAF(V600E)-positive papillary thyroid cancer: the role of endoscopic ultrasound-guided biopsy and response to sorafenib therapy.
    Alzahrani AS; AlQaraawi A; Al Sohaibani F; Almanea H; Abalkhail H
    Thyroid; 2012 May; 22(5):536-41. PubMed ID: 22435913
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of BRAF V600E mutation detection of fine-needle aspiration biopsy on diagnosis and treatment guidance of papillary thyroid carcinoma.
    Qi W; Shi C; Zhang P; Feng L; Wang J; Chen D
    Pathol Res Pract; 2020 Aug; 216(8):153037. PubMed ID: 32703500
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Noninferior response in BRAF(V600E) mutant nonmetastatic papillary thyroid carcinoma to radioiodine therapy.
    Li J; Liang J; Zhao T; Lin Y
    Eur J Nucl Med Mol Imaging; 2016 Jun; 43(6):1034-9. PubMed ID: 26780618
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.